Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026)
Krystal Biotech (KRYS) posted EBITDA Margin of 50.17% for Q2 2026, up 7.80 percentage points from 42.38% a year earlier and up 2.74 percentage points from the prior quarter.
Powered by 
Analysis
Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Krystal Biotech was 46.22%, up 5.88 percentage points year-over-year; for FY2025, it was 42.92%, up 18.22 percentage points from FY2024.
- In prior years, Krystal Biotech's EBITDA Margin was 24.70% in FY2024 (+233.55 pp) and -208.85% in FY2023.
- The Q2 2026 figure stands as the highest quarterly EBITDA Margin in data going back to Q3 2023.
- On a year-over-year basis, EBITDA Margin increased in seven of the last eight quarters, with an average year-over-year change of +57.98 percentage points.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q3 2024, with a gain of 322.50 percentage points; the weakest was Q4 2025, with a drop of 4.19 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was 47.43% (Q1 2026), 42.76% (Q4 2025) and 43.74% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Krystal Biotech | 9.98 Bn | 6.75 Bn | 112.79 Mn | 50.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.17% |
| Mar 31, 2026 | 47.43% |
| Dec 31, 2025 | 42.76% |
| Sep 30, 2025 | 43.74% |
| Jun 30, 2025 | 42.38% |
| Mar 31, 2025 | 42.70% |
| Dec 31, 2024 | 46.94% |
| Sep 30, 2024 | 28.35% |
| Jun 30, 2024 | 14.75% |
| Mar 31, 2024 | -11.60% |
| Dec 31, 2023 | 11.28% |
| Sep 30, 2023 | -294.14% |
API Access
Krystal Biotech EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "KRYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=KRYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();